AR117994A1 - METHODS TO TREAT TRIPLE NEGATIVE BREAST CANCER USING A HUMAN ERBB-2 MUTANT PROTEIN - Google Patents

METHODS TO TREAT TRIPLE NEGATIVE BREAST CANCER USING A HUMAN ERBB-2 MUTANT PROTEIN

Info

Publication number
AR117994A1
AR117994A1 ARP200100292A ARP200100292A AR117994A1 AR 117994 A1 AR117994 A1 AR 117994A1 AR P200100292 A ARP200100292 A AR P200100292A AR P200100292 A ARP200100292 A AR P200100292A AR 117994 A1 AR117994 A1 AR 117994A1
Authority
AR
Argentina
Prior art keywords
erbb
mutant
breast cancer
negative breast
triple negative
Prior art date
Application number
ARP200100292A
Other languages
Spanish (es)
Inventor
Mara Florencia Chervo
Patricia Virginia Elizalde
Original Assignee
Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet filed Critical Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Publication of AR117994A1 publication Critical patent/AR117994A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un método para tratar el cáncer de mama triple negativo en un sujeto, que comprende administrar una secuencia de ácidos nucleicos que codifica un polipéptido de ErbB-2 mutante en una cantidad efectiva para inhibir la proliferación de células cancerosas, en donde el ErbB-2 mutante carece de una señal de localización nuclear funcional, no puede translocarse al núcleo de la célula en la que está presente y funciona como un inhibidor dominante negativo de ErbB-2 endógeno al inhibir la translocación nuclear de ErbB-2 endógeno en la célula en la que está presente el mutante, en donde el polipéptido de ErbB-2 mutante retiene la actividad intrínseca de la tirosina quinasa y no inhibe la actividad de la tirosina quinasa de ErbB-2 endógeno.A method of treating triple negative breast cancer in a subject, comprising administering a nucleic acid sequence encoding a mutant ErbB-2 polypeptide in an amount effective to inhibit the proliferation of cancer cells, wherein the mutant ErbB-2 lacks a functional nuclear localization signal, cannot translocate to the nucleus of the cell in which it is present, and functions as a dominant negative inhibitor of endogenous ErbB-2 by inhibiting the nuclear translocation of endogenous ErbB-2 in the cell in which mutant is present, wherein the mutant ErbB-2 polypeptide retains intrinsic tyrosine kinase activity and does not inhibit endogenous ErbB-2 tyrosine kinase activity.

ARP200100292A 2019-02-05 2020-02-04 METHODS TO TREAT TRIPLE NEGATIVE BREAST CANCER USING A HUMAN ERBB-2 MUTANT PROTEIN AR117994A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962801282P 2019-02-05 2019-02-05

Publications (1)

Publication Number Publication Date
AR117994A1 true AR117994A1 (en) 2021-09-08

Family

ID=70005649

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100292A AR117994A1 (en) 2019-02-05 2020-02-04 METHODS TO TREAT TRIPLE NEGATIVE BREAST CANCER USING A HUMAN ERBB-2 MUTANT PROTEIN

Country Status (2)

Country Link
AR (1) AR117994A1 (en)
WO (1) WO2020161614A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2544680T3 (en) * 2010-03-11 2015-04-27 Merrimack Pharmaceuticals Inc USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
US9427458B2 (en) * 2010-07-22 2016-08-30 Consejo Nacional De Investigaciones Cientificas Y Tecnicas, Conicet Methods for inhibiting cancer cell proliferation

Also Published As

Publication number Publication date
WO2020161614A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
Demaria et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
Kanavy et al. Ultraviolet radiation and melanoma
Lu et al. miR-654-5p targets GRAP to promote proliferation, metastasis, and chemoresistance of oral squamous cell carcinoma through Ras/MAPK signaling
BR112012022802A2 (en) use of an erbb3 inhibitor, and method of suppressing cell growth and breast cancer tumor
CN102154482B (en) Application of calcium activated chloride channels ANO1/TMEM16A in diagnosis and treatment of prostate cancer
BR112015033053A2 (en) cancer treatment method in a subject, method of stimulating the immune system in a subject, method of increasing the distribution of an anticancer agent to a tumor cell, composition, and kit
EA202190474A1 (en) MICRO-RNA THERAPY AGAINST LCP-1-POSITIVE TUMORS
Zhang et al. ETS-1: A potential target of glycolysis for metabolic therapy by regulating glucose metabolism in pancreatic cancer
MX2020013535A (en) Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment.
de Llobet et al. Development and characterization of an isogenic cell line with a radioresistant phenotype
Lu PKM2 functions as a histone kinase
AR117994A1 (en) METHODS TO TREAT TRIPLE NEGATIVE BREAST CANCER USING A HUMAN ERBB-2 MUTANT PROTEIN
Adane et al. Prevalence of Coenuruscerebralis in Small Ruminants Slaughtered at Hashim Export Abattoir, Debre Zeit, Central Oromia
Sai et al. Carbon-ion beam irradiation and the miR-200c mimic effectively eradicate pancreatic cancer stem cells under in vitro and in vivo conditions
Miao et al. Telomere-mitochondrion links contribute to induction of senescence in MCF-7 cells after carbon-ion irradiation
Hamunyela et al. A cocktail of specific inhibitors of HER-2, PI3K, and mTOR radiosensitises human breast cancer cells
Endo et al. The FLCN-TFE3 axis regulates macrophage activation through cellular metabolism
CN104611429B (en) Application of miR-10b (micro ribonucleic acid-10b) gene to regulation of gastric cancer gene expression
BR112016008202A2 (en) BREAST CANCER PROGNOSIS DETERMINATION METHODS
Fukawa et al. THE CONTRIBUTION OF HGF-MET-MMP1 SIGNALING IN BLADDER CANCER INVASION, AND MET INHIBITOR AS A POTENTIAL THERAPEUTIC OPTION FOR INVASIVE BLADDER CANCER: MP58-17
MX2018008707A (en) Methods and compositions for use in the prevention, treatment and/or alleviation of cancer.
Liu et al. MiR-139 Affects Radioresistance in Esophageal Cancer by Targeting the PDK1/AKT/Cyclin D1 Signaling Pathway
HU et al. Expression of matrix metalloproteinase-3 in rat retina after acute High intraocular pressure
Zheng et al. Effect of mlncRNA2Y on the expression of P2X_3 receptor in primary cultured dorsal root ganglion neurons